Member Info for Bella6532

I'm a bit behind on what the official line is from Avacta...so correct me if I'm wrong...I thought they wanted a Partnership to take AVA6000 forward and the Pipeline will be Licenced either on an exclusive basis or non-exclusive basis.

Avacta is an R&D company and AVA6000 right now has generated loads of data in the lab and in trials so it's the foundation stone for the rest of the pipeline and not something just to sell off.

Will you stop comparing apples with oranges. AVA6000 is msde up of two parts...

PreCision the delivery system which is the Avacta part and the Payload which is another companies drug.

PRECISION WORKS....it delivers the payload to the tumour bipassing all other bits in the body with minimal side effects at much higher levels than is currently the norm.

Also these are Safety Trials not Efficacy Trials. Efficacy at this stage is a bonus and that's down to the payload not PreCision.

Finally...cancer isn't always what kills people...many die because they refuse to continue with treatment or the treatment itself damages/weakens the body so much other infections take hold and kill...

The markets only care about money not science. AIM is for the private investors and ii's who make pocket money on the back of fundraisers.

Pharma on the other hand are a bunch of copycats and all dive into well subscribed research areas once one of their mates jumps in first. Right now Avacta is pretty much in a space of it's own which really messes with Pharmas heads...plus it's very much early days trials wise.

The BIO International Convention is the world's largest gathering of biotechnology, pharmaceutical, and life sciences leaders. Hosted by the Biotechnology Innovation Organization (BIO), it brings together over 20,000 industry professionals from more than 70 countries to facilitate strategic collaboration, clinical partnering, and innovation.Key details for the current event include:Dates: June 22–25, 2026Location: San Diego Convention Center, San Diego, California, USAKey Focus Areas: Infectious diseases, cell and gene therapy, oncology, digital health, biomanufacturing, and investment trends.

HarChris...'The first drug in development going after very challenging heterogenous rare cancer types was never about a cure and everything to do with being a kinder therapy and extending life.'

Something not mentioned is affordability...the news this morning about a possible pill instead of chemo for pancreatic cancer still has side effects, only extends life for another 6 months at best and will cost roughtly £8000 per month....would the NHS fund this at this price for only 6 month life extension at best???

PreCision should be a relatively cheap product to make and is carrying existing tried, tested, approved off the shelf drugs. With little or no side effects, no MTD, we are seeing in the results so far good life extension and efficacy on very, very sick patients. Now what sort of results will we get at early diagnosis stage. As AI is used more and more in the diagnostic stages then our results could just get better and better...as long as patients can get seen/diagnosed!!!!!

28-May-26 15:57:42 75.00 100,000 Unknown* 75.00k O

28-May-26 16:06:02 75.50 106,753 Unknown* 80.60k O

29-May-26 16:29:14 78.70 3,000 Sell* 2,361 O

Let the fun begin...should see a steady rise now over next couple of weeks (if history repeats itself)...and could break £1 mark...😉

Follow the money....

How keen will RH be in getting a dual listing ...Nasdaq/AIM

How many articles are now AI generated???...

Which do we trust?

'Key dates: Full abstracts published 21 May 2026 at 5pm ET. Formal presentation at ASCO McCormick Place Chicago 30 May–3 June 2026. Every pharma BD team, oncology KOL and institutional investor in the room simultaneously. Partnership conversations currently in diligence will accelerate the moment the abstract is published.'

'ASCO 2026 CONFIRMED. AVA6000 Phase 1a/1b data will be presented at ASCO Annual Meeting, Chicago, 30 May–3 June 2026. Abstract title already published: "A phase Ia/Ib trial of FAP-Dox (AVA6000)... and activity against salivary gland cancers." Full abstracts release: 21 May 2026 at 5pm ET. The title is a deliberate efficacy signal — "activity" is not used in ASCO titles for safety-only readouts. Combined 1a/1b dataset (~40-50 SGC patients) with mature follow-up. First public TNBC and STS cohort data. Phase 1b enrolled in first and second line setting — commercially relevant patients, not just heavily pre-treated. The company has stated Phase 2 is planned subject to partner.'

Timster...in here...

https://storage.googleapis.com/avacta-analysis/avacta_deep_research.html

Second meeting...

13:16

30 May – 3 Jun 2026

ASCO Annual Meeting, Chicago — formal presentation of Phase 1a/1b AVA6000 data. Every major pharma BD team, oncology KOL, and institutional investor in the room simultaneously.

AI can't tell you how the patients feel/react to dossage plus they have to make sure there aren't signs of resistance..toxic build up...regrowth..new growth etc etc...

Covid didn't help...

'The Group's revenue to destinations outside the UK amounted to 100% (2024: 100%) of total revenue. The revenue analysis below is based on the country of registration of the customer:

South Korea

2024 £113,000

2025 £113,000'

113

BV...it all depends on what value the Pharmas put on a delivery mechanism which takes their nastiest chemo drugs at potentially much higher doses to tumours around the body (no matter where they might lurk) avoiding damage to non-tumour cells/vital organs with minimal, if any, side effect to the patient. In addition, there is also the potential to deliver other drugs alongside such as anti-resistance goodies. The guys who pace the floors at expos etc need the numbers/data (lots of it) to take to their office bound money men...nobody takes millions out of the safe without proof...

When the girst Lemming jumps the rest will follow.

When the first Pharma jumps head will surely be turned and more will follow...happens all the time...one in, all in...because they are so scared of missing out on the next mega money makings new drug.

Read Outs = Better Prospects for a Deal.

The Better the Read Out = The Better the Deal.

I suggest you all read sections: Hidden Signals and Science Day